Avedro Optimistic on Future of CXL (OIS@AAO 2016) скачать в хорошем качестве

Avedro Optimistic on Future of CXL (OIS@AAO 2016)

"Anterior Segment Company Showcase: Avedro" panel from Healthegy's OIS@AAO 2016: Presenter: Rajesh K. Rajpal, MD, Chief Medical Officer – Avedro Avedro’s chief medical officer, Rajesh K. Rajpal, MD, said 2016 marked the first US Food and Drug Administration approval of a collagen cross-linking (CXL) device, Avedro’s Photrexa Viscous, Photrexa, and KXL system. “Globally, there have been more than 140,000 cross-linking procedures performed,” Dr. Rajpal said. “In the US, our system is approved for progressive keratoconus and post-refractive corneal ectasia.” Outside the US, however, CXL is performed with “accelerated technology” and in combination with LASIK, photorefractive keratectomy (PRK), and the small incision lenticule extraction (SMILE) procedures. Avedro is ramping up its US sales force, and already has 42 international distributors. “Avedro boasts an experienced management team, and we are a global commercial enterprise,” Dr. Rajpal stated. “PiXL is the future of refractive CXL,” he said. PiXL – photorefractive instrastomal cross-linking – is best described as ultraviolet A patterning applied to the center (myopia), midperiphery (hyperopia), or a bowtie-shaped region (astigmatism) of a riboflavin-soaked cornea, and already has the CE mark as a non-invasive refractive procedure. Continue Reading About Avedro Here: http://ois.net/avedro-optimistic-on-f... For more on Ophthalmology Innovation News & Events visit: http://ois.net/